/R E P E A T -- Video B-Roll available via CNW - Merck and Schering-Plough to Complete Merger/ Nov 4, 2009
New Merck Will Begin Combined Operations on November 4th, 2009. TORONTO, Nov. 3 /CNW/ - The following video is available by satellite. (Canada Newswire)
Results from two Canadian studies confirm sustained viral response rates seen in hepatitis C patients treated with PEGETRON(R) Nov 2, 2009
- Canadian POWeR and REDIPEN(R) Programs presented at the American Association for the Study of Liver Diseases Annual Meeting. " These results reinforce the notion that outcomes achieved with PEGETRON across a large number of clinical trials are consistent and could be generalized to real-life clinical practice.(3) The Future of Hepatitis C Therapy In addition to the POWeR and REDIPEN studies, clinical trial data for Schering-Plough's investigational HCV protease inhibitors boceprevir and... (Canada Newswire)
Schering-Plough Chairman and CEO Fred Hassan Joins Time Warner's Board of Directors Oct 30, 2009
Mr. Hassan, 63, is Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation ... Mr. Hassan became Chairman and CEO of Schering-Plough Corporation in 2003. (Yahoo! Wire -- Entertainment News)
Judge rejects Schering-Plough tax refund request Sep 1, 2009
Reportlinker Adds Schering-Plough Corporation: PharmaVitae Profile ... Innovate , the ninth annual joint symposium of BioNJ and Pennsylvania Bio, will feature Fred Hassan, chairman and CEO of Schering-Plough Corporation of Kenilworth, NJ, as the luncheon keynote speaker on Tuesday, November 17, 2009. (Fresno Bee -- Business)
U.S. Court Rejects Efforts By Schering-Plough Corporation To Repatriate $690 Million In Offshore Earnings Without Paying Taxes Sep 1, 2009
Text hiding to spacing. WASHINGTON, Aug. 31 /PRNewswire-USNewswire/ -- A federal court in Newark, N.J., denied Schering-Plough Corp. a $473 million refund in connection with two transactions in which Schering-Plough sought to avoid taxation on $690 million in profits it repatriated from offshore subsidiaries into the United States. (PR Newswire)
Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) Aug 12, 2009
KENILWORTH, N.J., Aug. 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: ) today announced an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma, Inc. ("Orchid"), related to the generic manufacturing of certain formulations of CLARINEX(R) (desloratadine) ... SOURCE Schering-Plough Corporation. (PR Newswire)
Hepatitis C Infection: Treatment Options Equally Effective, Likelihood Of Success Known Early On Aug 4, 2009
Funding support for this study, which took place between March 2004 and June 2006, was provided by the Schering-Plough Corporation of Kenilworth, N.J., the brand manufacturer and provider of study drugs ribavirin (also known as Rebetol, F.D.A. approved since 1996) and peginterferon alfa-b (or Peg Intron, approved in 2001). Peginterferon alfa-a (or Pegasys, approved in 2002) is manufactured by Hoffman La Roche Inc., of Nutley, N.J.. (Science Daily)
New UN center proposal unveiled in SF Jul 31, 2009
Schering-Plough Corporation (NYSE: SGP) today reported a proposed settlement, subject to Court approval, to resolve litigation seeking to enjoin the planned merger with Merck Inc., and other forms of relief. The consolidated class action lawsuits, previously reported in the merger proxy statement/prospectus filed June 25, 2009, were filed in U.S. District Court for the District of New Jersey. (Fresno Bee -- State)
J&J unit wins $1.67 billion verdict vs Abbott Labs Jun 30, 2009
Centocor Ortho Biotech Inc. and Schering-Plough Corporation (NYSE: SGP) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) adopted a positive opinion recommending the approval of SIMPONI(TM) (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderate-to-severe, active rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) and severe, active ankylosing spondylitis (AS). Upon Commission... (Fresno Bee -- Business)
Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder Jun 2, 2009
KENILWORTH, N.J., June 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: ) today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for SYCREST(R) (asenapine) sublingual tablets for the treatment of schizophrenia and manic episodes associated with bipolar I disorder ... SOURCE Schering-Plough Corporation. (PR Newswire)
Centocor Ortho Biotech Data to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting May 29, 2009
Schering-Plough Corporation, under a licensing agreement, has exclusive rights to market the medication as CAELYX throughout the rest of the world, excluding Japan and Israel. For more information about DOXIL, please visit. (PR Newswire)
Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM) May 28, 2009
NEW BRUNSWICK, N.J., May 27 /PRNewswire-FirstCall/ -- In an arbitration demand filed today with the American Arbitration Association, Johnson & Johnson (NYSE: ) has requested a ruling that the agreement and plan of merger between Merck & Co., Inc., and Schering-Plough Corporation constitutes a change of control that would permit the termination of the agreements between Schering-Plough and Johnson & Johnson's subsidiary Centocor Ortho Biotech Inc., regarding the product REMICADE(R) (infliximab),... (PR Newswire)
Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD May 19, 2009
KENILWORTH, N.J., May 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: ) today announced changes to its global collaboration with Novartis for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD) ... About Schering-Plough Corporation ... SOURCE Schering-Plough Corporation. (PR Newswire)
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study Mar 13, 2009
KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Results of a Schering-Plough Corporation (NYSE: ) Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability ... SOURCE Schering-Plough Corporation. (PR Newswire)
WHAT THEY SAY: Read the press release Mar 10, 2009
Merck & Co., Inc. [] and Schering-Plough Corporation [] today announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction ... " Strategic Benefits of the Transaction -- Complementary Product Portfolios and Pipelines Focused on Key Therapeutic Areas: The combination significantly broadens Merck's portfolio of medicines - an engine for consistent,... (USA Today -- Money)
